ReviewBiologics : targets & therapy2020
Blinatumomab for the Treatment of Adult B-Cell Acute Lymphoblastic Leukemia: Toward a New Era of Targeted Immunotherapy.
Review in Biologics : targets & therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Efficacy of Chemotherapy-Free Regimens in the Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis.Clinical lymphoma, myeloma & leukemia · 2024Pooled it
- Preemptive interferon-α treatment could protect against relapse and improve long-term survival of ALL patients after allo-HSCT.Scientific reports · 2020Trial
- Efficacy and safety of blinatumomab combination therapy in high-risk B-cell acute lymphoblastic leukemia: A systematic review and meta-analysis.Oncology letters · 2026Article
- Novel Therapeutic Approaches in Pediatric Acute Lymphoblastic Leukemia.International journal of molecular sciences · 2025Review
- Measurable residual disease monitoring in AML: Prospects for therapeutic decision-making and new drug development.American journal of hematology · 2025Review
- Understanding the causes of high mortality among adult acute leukaemia patients in Armenia.Ecancermedicalscience · 2025Article
- Bispecific antibodies as powerful immunotherapeutic agents for urological cancers: Recent innovations based on preclinical and clinical evidence.International journal of biological sciences · 2025Review
- Bispecific immunotherapy based on antibodies, T-cell receptors, and aptamers: mechanisms of action, adverse effects, and future perspectives.Frontiers in immunology · 2025Review
- Article
- Human plasma cells engineered to secrete bispecifics drive effective in vivo leukemia killing.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Outcomes of children treated for relapsed or refractory acute lymphoblastic leukemia: A single tertiary care center experience.Cancer reports (Hoboken, N.J.) · 2024Article
- Real-world evidence on treatment pattern, effectiveness, and safety of blinatumomab in Chinese patients with B-cell acute lymphoblastic leukemia.Investigational new drugs · 2024Article
- Novel Biomarkers and Molecular Targets in ALL.Current hematologic malignancy reports · 2024Review
- End-to-end approach for the characterization and control of product-related impurities in T cell bispecific antibody preparations.International journal of pharmaceutics: X · 2023Article
- Recent advances in the liposomal nanovesicles based immunotherapy in the treatment of cancer: A review.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023Review
- Positioning blinatumomab in the frontline of adult B-cell acute lymphoblastic leukemia treatment.Frontiers in oncology · 2023Review
- Anti-ROR1 CAR-T cells: Architecture and performance.Frontiers in medicine · 2023Review
- Targeting CD19 in diffuse large B-cell lymphoma: An expert opinion paper.Hematological oncology · 2022Review
- BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro.Journal of cancer research and clinical oncology · 2022Article
- Bispecific Antibody-Bound T Cells as a Novel Anticancer Immunotherapy.Biomolecules & therapeutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Several therapeutic advancements in the treatment of B-cell acute lymphoblastic leukemia (ALL) have surfaced in the past decade, primarily driven by an increased understanding of the immunopathobiology of this disease. The clinical use of blinatumomab, a bispecific antibody that coordinates cytotoxic CD3+ T lymphocytes and CD19+ lymphoblasts, has resulted in improved outcomes in both relapsed/refractory and minimal residual disease-positive B-cell ALL. Promising emerging data also demonstrate the efficacy of this agent in the frontline setting and in combination regimens. Uncertainty remains regarding the optimal sequencing and combination of blinatumomab with cytotoxic chemotherapy and other emerging agents. The pharmacology and clinical data on blinatumomab for adult B-cell ALL, both as monotherapy and in combinations, will be reviewed herein.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.